ПОДХОДЫ К НАЗНАЧЕНИЮ АНТИКОАГЛЯНТОВ ПРИ ВЫПОЛНЕНИИ КАРДИОВЕРСИИ ПАЦИЕНТАМ С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ
И. В. Зотова
ФГБУ ДПО «Центральная государственная медицинская академия» УД Президента РФ, Москва

Ключевые слова

фибрилляция предсердий
кардиоверсия
антикоагулянты
клинический протокол

Как цитировать

[1]
И. В. Зотова, ПОДХОДЫ К НАЗНАЧЕНИЮ АНТИКОАГЛЯНТОВ ПРИ ВЫПОЛНЕНИИ КАРДИОВЕРСИИ ПАЦИЕНТАМ С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ, КМКВ, вып. 4, сс. 126-136, дек. 2019.

Аннотация

В статье представлен авторский клинический протокол назначения антикоагулянтов при выполнении кардиоверсии пациентам с фибрилляцией предсердий в различных клинических ситуациях. Обсуждаются данные по частоте развития тромбоэмболических осложнений, возможности использования различных типов антикоагулянтов, проводится сравнительный анализ современных клинических рекомендаций.

Литература

1. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2016; 50(5): e1-e88.
2. Airaksinen KE, Gronberg T, Nuotio I, Nikkinen M, Ylitalo A, Biancari F et al. Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish CardioVersion) study. J Am Coll Cardiol. 2013; 62(13): 1187-92.
3. Nuotio I, Hartikainen JE, Gronberg T, Biancari F, Airaksinen KE. Time to cardioversion for acute atrial fibrillation and thromboembolic complications. JAMA. 2014; 312(6): 647-9. doi: 10.1001/jama.2014.3824.
4. Gronberg T, Hartikainen JE, Nuotio I, Biancari F, Ylitalo A, Airaksinen KE. Anticoagulation, CHA2DS2VASc Score, and Thromboembolic Risk of Cardioversion of Acute Atrial Fibrillation (from the FinCV Study). Am J Cardiol. 2016; 117(8): 1294-8. doi: 10.1016/j.amjcard.2016.01.024.
5. Hansen ML, Jepsen RM, Olesen JB, Ruwald MH, Karasoy D, Gislason GH et al. Thromboembolic risk in 16 274 atrial fibrillation patients undergoing direct current cardioversion with and without oral anticoagulant therapy. Europace. 2015; 17(1): 18-23. doi: 10.1093/europace/euu189.
6. Zapolski T, Wysokinski A. Stunning of the left atrium after pharmacological cardioversion of atrial fibrillation. Kardiol Pol. 2005; 63(3): 254-62.
7. Okcun B, Yigit Z, Arat A, Baran T, Kucukoglu MS. Stunning of the left atrium after conversion of atrial fibrillation: predictor for maintenance of sinus rhythm? Echocardiography. 2005; 22(5): 402-7.
8. Khan IA,. Transient atrial mechanical dysfunction (stunning) after cardioversion of atrial fibrillation and flutter. Am Heart J. 2002; 144(1): 11-22.
9. Berger M Schweitzer P. Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a retrospective analysis. Am J Cardiol. 1998; 82(12): 1545-7.
10. Lip GYH, Banerjee A, Boriani G, Chiang C, Fargo R, Freedman B et al. Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report. Chest. 2018; 154(5): 1121-1201. doi: 10.1016/j.chest.2018.07.040.
11. Andrade JG, Verma A, Mitchell LB, Parkash R, Leblanc K, Atzema C et al. 2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. Can J Cardiol. 2018; 34(11): 1371-1392. doi: 10.1016/j.cjca.2018.08.026.
12. Klein AL, Grimm RA, Murray RD, Apperson-Hansen C, Asinger RW, Black IW et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med. 2001; 344(19): 1411-20.
13. Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma CS, Le Heuzey JY et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014; 35(47): 3346-55. doi: 10.1093/eurheartj/ehu367.
14. Goette A, Merino JL, Ezekowitz MD, Zamoryakhin D, Melino M, Jin J et al. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet. 2016; 388(10055): 1995-2003. doi: 10.1016/S0140-6736(16)31474-X
15. Carerj S, Micari A, Di Rosa S, Pugliatti P, Cerrito M, Zito C et al. Thrombo-embolic risk evaluation in patients with atrial fibrillation. Role of echocardiography. Minerva Cardioangiol. 2003; 51(3): 287-93.
16. von der Recke G, Schmidt H, Illien S, Luderitz B, Omran H. Use of transesophageal contrast echocardiography for excluding left atrial appendage thrombi in patients with atrial fibrillation before cardioversion. J Am Soc Echocardiogr. 2002; 15(10 Pt 2): 1256-61.
17. Herring N, Page SP, Ahmed M, Burg MR, Hunter RJ, Earley MJ et al. The Prevalence of Low Left Atrial Appendage Emptying Velocity and Thrombus in Patients Undergoing Catheter Ablation for Atrial Fibrillation on Uninterrupted Peri-procedural Warfarin Therapy. J Atr Fibrillation. 2013; 5(6): 761. doi: 10.4022/jafib.761.
18. Исаева М.Ю., Зотова И.В., Алехин М.Н., Гогин Г.Е., Привалов А.В., Ваниева О.С. и др. Выявление тромбоза ушка левого предсердия у больных с мерцательной аритмией и факторами риска тромбоэмболических осложнений: роль чреспищеводной эхокардиографии и мультиспиральной компьютерной томографии. Кардиология, 2007; 47: 40-45.
19. Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011; 123(2): 131-6. doi: 10.1161/CIRCULATIONAHA.110.977546.
20. Piccini JP, Stevens SR, Lokhnygina Y, Patel MR, Halperin JL, Singer DE et al. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol. 2013; 61(19): 1998-2006. doi: 10.1016/j.jacc.2013.02.025.
21. Flaker G, Lopes RD, Al-Khatib SM, Hermosillo AG, Hohnloser SH, Tinga B et al. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol. 2014; 63(11): 1082-7. doi: 10.1016/j.jacc.2013.09.062.
22. Plitt A, Ezekowitz MD, De Caterina R, Nordio F, Peterson N Giugliano RP et al. Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48. Clin Cardiol. 2016; 39(6): 345-6. doi: 10.1002/clc.22537.
23. Ezekowitz MD, Pollack CV, Halperin JL, England RD, VanPelt Nguyen S, Spahr J et al. Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial. Eur Heart J. 2018; 39(32): 2959-71. doi: 10.1093/eurheartj/ehy148.
24. Renda G, Ricci F, De Caterina R. Non-Vitamin K Antagonist Oral Anticoagulants for Cardioversion in Atrial Fibrillation: An Updated Meta-analysis. Am J Med. 2017; 130(4): 457-61. doi: 10.1016/j.amjmed.2016.09.023.
25. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018; 39(16): 1330-1393. doi: 10.1093/eurheartj/ehy136.
26. Whiteside H, Brown K, Nagabandi A, Ratanapo S, Sharma G et al. Impact of anticoagulation on resolution of left atrial appendage thrombi. Journal of the American College of Cardiology. 2018; 71(11 Supplement): A297. doi: 10.1016/S0735-1097(18)30838-6
27. Lip GY, Hammerstingl C, Marin F, Cappato R, Meng IL, Kirsch B et al. Left atrial thrombus resolution in atrial fibrillation or flutter: Results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF). Am Heart J. 2016; 178: 126-34. doi: 10.1016/j.ahj.2016.05.007.
28. Ferner M, Wachtlin D, Konrad T, Deuster O, Meinertz T, von Bardeleben S et al. Rationale and design of the RE-LATED AF--AFNET 7 trial: REsolution of Left atrial-Appendage Thrombus--Effects of Dabigatran in patients with Atrial Fibrillation. Clin Res Cardiol. 2016; 105(1): 29-36. doi: 10.1007/s00392-015-0883-7.
29. Fleddermann A, Eckert R, Muskala P, Hayes C, Magalski A Main ML. Efficacy of Direct Acting Oral Anticoagulant Drugs in Treatment of Left Atrial Appendage Thrombus in Patients With Atrial Fibrillation. Am J Cardiol. 2019; 123(1): 57-62. doi: 10.1016/j.amjcard.2018.09.026.
30. Рычков А.Ю., Хорькова Н.Ю., Белокурова А.В., Ярославская Е.И. Прямые оральные антикоагулянты при тромбозе левого предсердия у пациентов с фибрилляцией предсердий. Вестник аритмологии. 2018; 91: 60-63.